Sunday, 20 September 2026European Markets

VEON Stock Soars 18% As Trading Day Concludes!

Loading stream...

(VIANEWS) - VEON shares surge 18.51% on the AEX-Index Shares of VEON (AEX-Index: VEON.AS) experienced an extraordinary surge of 18.51% to EUR0.73 at 15:08 EST on Wednesday, continuing its upward trajectory from previous sessions. Despite being part of an AEX-Index that declined 0.57% overall (EUR732.50), this marked a distinct reversal in trend after five consecutive losses over previous five sessions; though overall this day exhibited negative signs.

About VEON

VEON Ltd is a telecom company founded in 1992 that offers mobile and fixed-line voice, data, wireless internet services to corporates, operators, consumers and mobile finance customers in Russia, Pakistan, Algeria, Uzbekistan Ukraine Bangladesh Kazakhstan Kyrgyzstan Georgia under various brands. Headquartered in Amsterdam the Netherlands.

Technical Analysis

VEON, the global telecom company, experienced an astonishing surge in trading volume today - 10.259.90 shares changed hands compared to its 50-day average volume of 98.830. This may indicate increased investor interest and potentially move the stock in either direction. Volatility analysis shows VEON as experiencing a negative 0.20% intraday variance over the last week, negative 0.21% over one month, and positive 2.19% variation over three months - indicative of some uncertainty surrounding this stock in recent times. According to the stochastic oscillator, an influential technical indicator designed to monitor overbought and oversold conditions, VEON stock currently appears oversold with a reading below 20 on its stochastic oscillator indicator, suggesting it may be undervalued and likely in for an upward price surge in due time. Overall, investors in VEON should keep a close eye on its price movements as well as any news or developments that could have an effect on its price. Investors may wish to consider any impact from COVID-19 pandemic on telecom industry performance as well as regulatory changes or market shifts which might alter performance of VEON shares.

Equity Analysis

Based on its financial data, VEON has an estimated trailing twelve months EPS of EUR0.26. This indicates that they earned this amount per share during the past twelve months - providing investors with vital insight into VEON's profitability. Additionally, the company boasts a trailing twelve months PE ratio of 2.81, which indicates that investors are willing to pay EUR2.81 per euro of annual earnings for every share in circulation. This ratio helps investors assess whether their stock may be over or undervalued; higher PE ratios indicate potential overvaluation while lower PE ratios could indicate possible undervaluation. Overall, VEON's earnings per share and PE ratio suggest it is profitable; however, investors should carefully assess current market conditions and other considerations before making investment decisions.

More news about VEON (VEON.AS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Boom Hits a Fork: Slowdown Calls Clash with Capex Confidence as Markets Get Nervous
Dario Amodei's repeated calls for a global slowdown in frontier AI development, echoed by Microsoft's new humanist AI code of conduct and FTC antitrust caution, are being publicly rejected by Nvidia and Meta leadership even as hyperscaler spending draws fresh skeptical scrutiny (Wachter's analysis, Burry-style overbuilding worries) and weak guidance from Adobe and a post-slowdown-comment selloff in GE Vernova signal investor jitters. Meanwhile wealth and security effects of the AI race keep compounding — Zhang Yiming's fortune surging on AI-driven ByteDance value, a Chinese hacking firm weaponizing AI against stolen government secrets, and low-quality AI-generated products (an AI sitcom, a spam-flooding agent platform) fueling backlash even as adoption races ahead.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Berkshire Hathaway
Both facts report Berkshire Hathaway's cash position on 2026-01-01 with identical observation timestamps, but claim vastly different values: 380 billion USD vs 400 USD. These cannot both be true for the same entity at the same point in time. The magnitude of the discrepancy (a factor of ~10^9) rules out rounding, unit conversion, or methodological differences.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,982
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,982 facts checked against source5,299 source documents archived
Query this data → isubstrate.com